艾滋病病毒/艾滋病有哪些新进展？中和性艾滋病病毒抗体：它们真的能起到保护作用吗？

What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?

作者信息

Jülg B, Goebel F D

机构信息

Dept. of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, 80336 Munich, Germany.

出版信息

Infection. 2005 Oct;33(5-6):405-7. doi: 10.1007/s15010-005-6505-y.

DOI:10.1007/s15010-005-6505-y

PMID:16258878

Abstract

Neutralizing antibodies work as a second line of defence. They are detected more or less in nearly every HIV-1-infected individual. 2G12, 2F5 and 4E10 represent antibodies with broadly neutralizing activity made from B cells of HIV- 1-infected humans. Unfortunately these antibodies are extremely rare and all attempts to elicit them via vaccine immunogens have failed. The discovery of autoreactive features of these antibodies could now explain why. Additionally, new results show the delayed viral rebound under antibody treatment in some HIV-1-infected individuals.

摘要

中和抗体作为第二道防线发挥作用。几乎在每一位感染HIV-1的个体中都能或多或少检测到它们。2G12、2F5和4E10代表了具有广泛中和活性的抗体，这些抗体由感染HIV-1的人类B细胞产生。不幸的是，这些抗体极其罕见，并且通过疫苗免疫原引发它们的所有尝试均告失败。现在，这些抗体自身反应性特征的发现或许可以解释其中的原因。此外，新的研究结果表明，在抗体治疗下，一些感染HIV-1的个体中病毒出现延迟反弹。